Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 11/20 | 0.71 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.44 |
| ▸ | MLYCD | O95822 | 2/20 | 0.43 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4341935 | 0.93 | MAPK14 (0.75) | MAPK14LMNAMLYCDHCAR2KMT2A | |
| SCHEMBL4328387 | 0.92 | MAPK14 (0.74) | MAPK14LMNAHSP90AA1MEN1KMT2A | |
| SCHEMBL4337091 | 0.92 | MAPK14 (0.76) | MAPK14LMNAHSP90AA1MLYCD | |
| SCHEMBL4337498 | 0.90 | MAPK14 (0.70) | MAPK14HSP90AA1 | |
| SCHEMBL4330141 | 0.90 | MAPK14 (0.76) | MAPK14LMNAMLYCDHCAR2SMN1; SMN2 | |
| SCHEMBL27744981 | 0.88 | MAPK14 (0.68) | MAPK14LMNAHSP90AA1MLYCDMEN1 | |
| SCHEMBL4347330 | 0.88 | MAPK14 (0.68) | MAPK14LMNAHSP90AA1KMT2ASMN1; SMN2 | |
| SCHEMBL4469515 | 0.88 | MAPK14 (0.76) | MAPK14LMNAMLYCDHCAR2SMN1; SMN2 | |
| SCHEMBL4333402 | 0.87 | MAPK14 (0.74) | MAPK14LMNAHSP90AA1MEN1KMT2A | |
| SCHEMBL4521201 | 0.87 | MAPK14 (0.81) | MAPK14LMNAMLYCDHCAR2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2036905-B1 | PYRIDYLISOXAZOLE DERIVATIVE | ASKA PHARM CO LTD (JP) | 2012-12-12 | — | — | EP | disclosed |
| US-8207203-B2 | Pyridylisoxazole derivatives | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2012-06-26 | — | — | US | disclosed |
| US-20090306145-A1 | Pyridylisoxazole Derivatives | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2009-12-10 | — | — | US | disclosed |
| EP-2036905-A1 | PYRIDYLISOXAZOLE DERIVATIVE | ASKA Pharmaceutical Co., Ltd. (JP) | 2009-03-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306145-A1 | Pyridylisoxazole Derivatives | CNKSR1, MAPK1, MAPK3 | MAPK14 43/4885LMNA 4792/4885HSP90AA1 2550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.